Roth Capital Has Bullish Outlook for CYCC FY2024 Earnings

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Equities research analysts at Roth Capital boosted their FY2024 earnings per share (EPS) estimates for Cyclacel Pharmaceuticals in a report released on Wednesday, November 13th. Roth Capital analyst J. Aschoff now expects that the biotechnology company will post earnings per share of ($1.95) for the year, up from their previous forecast of ($2.29). Roth Capital has a “Hold” rating on the stock. The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Cyclacel Pharmaceuticals’ Q4 2024 earnings at ($0.29) EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at $3.67 EPS and FY2028 earnings at $5.49 EPS.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.36. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Separately, StockNews.com began coverage on Cyclacel Pharmaceuticals in a research note on Friday. They issued a “sell” rating for the company.

Cyclacel Pharmaceuticals Trading Down 4.9 %

NASDAQ:CYCC opened at $0.37 on Friday. Cyclacel Pharmaceuticals has a 1-year low of $0.35 and a 1-year high of $6.00. The firm has a market capitalization of $804,474.00, a price-to-earnings ratio of -0.04 and a beta of 0.56. The business’s 50-day moving average price is $0.85 and its two-hundred day moving average price is $1.42.

Hedge Funds Weigh In On Cyclacel Pharmaceuticals

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC bought a new position in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned approximately 9.18% of Cyclacel Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 23.58% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.